Please assess the completion status of the following clinical trial:

Trial Title: Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inadequate response to conventional therapy including corticosteroids or are intolerant to, or have medical contraindications for conventional therapies~* UC diagnosed prior to screening, based on a biopsy collected at endoscopy~* Moderate to severe active UC with total Mayo score of 6 to 12, inclusive at baseline, and endoscopic Mayo sub-score, greater than or equal to 2~* Adenomatous polyps removed within last 5 years or at the screening visit prior to the first drug treatment~* Extensive colitis for ≥ 8 years, or disease limited to the left side of the colon for ≥10 years should have a colonoscopy to exclude the presence of dysplasia within 1 year prior to study inclusion or a colonoscopy to exclude the presence of malignancy at the screening visit~* No history of untreated latent or active Tuberculosis (TB) prior to screening~* Negative stool results for enteric pathogens~Exclusion Criteria:~* History of asthma~* History of autoimmune diseases~* History of hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Golimumab treatment (Type: EXPERIMENTAL): Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).